156 related articles for article (PubMed ID: 11781402)
1. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS.
Bech E; Lycke J; Gadeberg P; Hansen HJ; Malmeström C; Andersen O; Christensen T; Ekholm S; Haahr S; Höllsberg P; Bergström T; Svennerholm B; Jakobsen J
Neurology; 2002 Jan; 58(1):31-6. PubMed ID: 11781402
[TBL] [Abstract][Full Text] [Related]
2. A randomized clinical trial of valacyclovir in multiple sclerosis.
Friedman JE; Zabriskie JB; Plank C; Ablashi D; Whitman J; Shahan B; Edgell R; Shieh M; Rapalino O; Zimmerman R; Sheng D
Mult Scler; 2005 Jun; 11(3):286-95. PubMed ID: 15957509
[TBL] [Abstract][Full Text] [Related]
3. Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies.
Baker D; Eisen D
Cutis; 2003 Mar; 71(3):239-42. PubMed ID: 12661753
[TBL] [Abstract][Full Text] [Related]
4. Antiherpes virus-specific treatment and cognition in schizophrenia: a test-of-concept randomized double-blind placebo-controlled trial.
Prasad KM; Eack SM; Keshavan MS; Yolken RH; Iyengar S; Nimgaonkar VL
Schizophr Bull; 2013 Jul; 39(4):857-66. PubMed ID: 22446565
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
6. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
Fife KH; Warren TJ; Justus SE; Heitman CK;
Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
[TBL] [Abstract][Full Text] [Related]
7. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial.
Fife KH; Warren TJ; Ferrera RD; Young DG; Justus SE; Heitman CK; Burroughs SM
Mayo Clin Proc; 2006 Oct; 81(10):1321-7. PubMed ID: 17036557
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of valacyclovir in preventing recurrent herpes simplex virus infections associated with dental procedures.
Miller CS; Cunningham LL; Lindroth JE; Avdiushko SA
J Am Dent Assoc; 2004 Sep; 135(9):1311-8. PubMed ID: 15493396
[TBL] [Abstract][Full Text] [Related]
9. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
10. Long-term valacyclovir suppressive treatment after herpes simplex virus type 2 meningitis: a double-blind, randomized controlled trial.
Aurelius E; Franzen-Röhl E; Glimåker M; Akre O; Grillner L; Jorup-Rönström C; Studahl M;
Clin Infect Dis; 2012 May; 54(9):1304-13. PubMed ID: 22460966
[TBL] [Abstract][Full Text] [Related]
11. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
[TBL] [Abstract][Full Text] [Related]
12. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies.
Spruance SL; Jones TM; Blatter MM; Vargas-Cortes M; Barber J; Hill J; Goldstein D; Schultz M
Antimicrob Agents Chemother; 2003 Mar; 47(3):1072-80. PubMed ID: 12604544
[TBL] [Abstract][Full Text] [Related]
13. Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial.
Tyring SK; Plunkett S; Scribner AR; Broker RE; Herrod JN; Handke LT; Wise JM; Martin PA;
J Med Virol; 2012 Aug; 84(8):1224-32. PubMed ID: 22711350
[TBL] [Abstract][Full Text] [Related]
14. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial.
Abudalu M; Tyring S; Koltun W; Bodsworth N; Hamed K
Clin Infect Dis; 2008 Sep; 47(5):651-8. PubMed ID: 18637755
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.
Yi TJ; Walmsley S; Szadkowski L; Raboud J; Rajwans N; Shannon B; Kumar S; Kain KC; Kaul R; Tan DH
Clin Infect Dis; 2013 Nov; 57(9):1331-8. PubMed ID: 23946220
[TBL] [Abstract][Full Text] [Related]
16. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
17. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women.
Andrews WW; Kimberlin DF; Whitley R; Cliver S; Ramsey PS; Deeter R
Am J Obstet Gynecol; 2006 Mar; 194(3):774-81. PubMed ID: 16522412
[TBL] [Abstract][Full Text] [Related]
18. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G; Filippi M; Wolinsky JS
Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
[TBL] [Abstract][Full Text] [Related]
19. Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection.
Bras AP; Sitar DS; Aoki FY
Can J Clin Pharmacol; 2001; 8(4):207-11. PubMed ID: 11743593
[TBL] [Abstract][Full Text] [Related]
20. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
Barkhof F; Hulst HE; Drulovic J; Uitdehaag BM; Matsuda K; Landin R;
Neurology; 2010 Mar; 74(13):1033-40. PubMed ID: 20200338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
